IPP Bureau
Nanavati Max, Uzbekistan’s NVRH forge alliance to advance healthcare and training
By IPP Bureau - October 06, 2025
Wockhardt submits NDA to USFDA for Zidebactam-Cefepime injection
By IPP Bureau - October 05, 2025
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
FDA approves Roche’s Tecentriq + lurbinectedin as first-line maintenance therapy for lung cancer
By IPP Bureau - October 05, 2025
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
AbbVie’s Natrelle awarded supplier agreement from Vizient
By IPP Bureau - October 05, 2025
This agreement grants Vizient clients enhanced access to Natrelle, the broadest selection of breast implant options on the market
BMS’s anti-MTBR-Tau granted fast track designation by FDA for Alzheimer’s disease
By IPP Bureau - October 05, 2025
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Takeda exits cell therapy research
By IPP Bureau - October 05, 2025
Takeda will seek an external partner to leverage its cell therapy platform technologies
Amgen’s Phase III data supports FDA label expansion of Repatha
By IPP Bureau - October 05, 2025
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
AstraZeneca Pharma India receives sale, distribution approval from CDSCO for Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder
By IPP Bureau - October 04, 2025
Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
Lupin launches Liraglutide injection in US
By IPP Bureau - October 04, 2025
Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk
Briefs: Panacea Biotec, Lotus Eye Hospital and Uflex
By IPP Bureau - October 04, 2025
Panacea Biotec receives Rs. 315 crore LoA from UNICEF
FDA issues CRL for Sentynl’s copper histidinate for treatment of Menkes disease
By IPP Bureau - October 04, 2025
Supriya Lifescience’s Ambernath facility receives WHO GMP certification
By IPP Bureau - October 04, 2025
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
IPA welcomes Dr. Sharvil Patel as President and Glenn Saldanha as Vice President
By IPP Bureau - October 04, 2025
Genmab to acquire Merus for $8 billion
By IPP Bureau - October 03, 2025
Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
A. P. Rameswara Rao appointed National President of BDMAI
By IPP Bureau - October 03, 2025
A Post Graduate in Science faculty and has a wide experience spanning over 35 years in the field of manufacturing Bulk Drugs and Active Pharmaceutical Intermediaries
